Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes.
To evaluate the oncologic outcomes of nephron-sparing surgery (NSS) for localized chromophobe renal cell carcinoma (cRCC).



We performed a multicenter international study involving the French Network for Research on Kidney Cancer (UroCCR) and 5 international teams. Data from 808 patients treated with NSS between 2004 and 2014 for non-clear cell RCCs were analyzed.



We included 234 patients with cRCC. There were 123 (52.6%) females. Median age was 61 (23-88) years. Median tumor size was 3 (1-11)cm. A positive surgical margin was identified in 14 specimens (6%). Pathologic stages were T1, T2, and T3a in 202 (86.3%), 9 (3.8%), and 23 (9.8%) cases, respectively. After a mean follow-up of 46.6 ± 36 months, 2 (0.8%) patients experienced a local recurrence. No patient had metastatic progression, and no patient died from cancer. Three-years estimated cancer-free survival and cancer-specific survival were 99.1% and 100%, respectively.



Oncological results of NSS for localized cRCC are excellent. In this series, only 2 patients had a local recurrence, and no patient had metastatic progression or died from cancer.
Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Angers University Hospital, Angers, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. Electronic address: pibigot@chu-angers.fr.
Pierre
P
Bigot
Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Bordeaux University Hospital, Bordeaux, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Jean-Christophe
JC
Bernhard
French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Lille University Hospital, Lille, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Vincent
V
Flamand
USC Institute of Urology, University of Southern California, Los Angeles, CA; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Inderbir
I
Gill
Department of Urology, Pontchaillou University Hospital, Rennes, France; French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Grégory
G
Verhoest
French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Toulouse University Hospital, Toulouse, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Jean Baptiste
JB
Beauval
French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Rouen University Hospital, Rouen, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
François Xavier
FX
Nouhaud
Department of Urology, University Hospital of Ankara, Ankara, Turkey; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Evren
E
Suer
Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; Department of Urology, Saint-Louis University Hospital, APHP, Paris, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Guillaume
G
Ploussard
Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; Department of Urology, Clinique Jules Vernes, Nantes, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Jean François
JF
Hetet
Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; Department of Urology, Nantes University Hospital, Nantes, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Jérôme
J
Rigaud
Department of Urology, University Hospital of Oslo, Oslo, Norway; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Eduard
E
Baco
Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; Department of Urology, Reims University Hospital, Reims, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Stéphane
S
Larré
Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; Department of Urology, Groupe hospitalier Diaconesses, Paris, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Philippe
P
Sebe
Department of Urology, Dijon University Hospital, Dijon, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Nicolas
N
Koutlidis
French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Limoges University Hospital, Limoges, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Aurélien
A
Descazeaud
Department of Urology, University Hospital of Kumamoto, Kumamoto, Japan; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Masatoshi
M
Eto
Department of Urology, Caen University Hospital, Caen, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Arnaud
A
Doerfler
Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; Department of Urology, La Pitié Salpetrière, APHP, Paris, France; Faculty of Medicine Pierre and Marie Curie, University Paris 6, Paris, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Morgan
M
Roupret
Department of Urology, Bordeaux University Hospital, Bordeaux, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Nam Son
NS
Vuong
Department of Urology, Lille University Hospital, Lille, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Boris
B
Reix
USC Institute of Urology, University of Southern California, Los Angeles, CA; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Toru
T
Matsugasumi
Department of Urology, Groupe hospitalier Diaconesses, Paris, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Adnan El
AE
Bakri
Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; Medical Oncology Department, University Paris 11, Villejuif, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Laurence
L
Albiges
Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Toulouse University Hospital, Toulouse, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Michel
M
Soulié
Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Medical Oncology Department, University Paris 11, Villejuif, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Jean-Jacques
JJ
Patard
Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, HEGP, APHP, Paris, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Arnaud
A
Méjean
Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Karim
K
Bensalah
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000601:surgery*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology / Q000601:surgery*; D008297:Male; D000072662:Margins of Excision; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000601:surgery; D018365:Neoplasm, Residual; D009399:Nephrons; D059351:Organ Sparing Treatments; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult
Chromophobe renal carcinoma; Nephron-sparing surgery; Oncologic outcomes
Urology. 2009 Oct;74(4):842-5
19628262
J Urol. 2009 Oct;182(4):1271-9
19683266
Eur Urol. 2006 May;49(5):798-805
16442207
Chest. 2007 Aug;132(2):679-84
17505035
Br J Urol. 1996 Aug;78(2):183-6
8813909
Eur Urol. 2015 Apr;67(4):683-9
25282367
J Urol. 2005 Jun;173(6):1893-6
15879770
J Urol. 2009 Jan;181(1):55-61; discussion 61-2
19012918
Am J Surg Pathol. 2002 Mar;26(3):281-91
11859199
Eur Urol. 2015 May;67(5):913-24
25616710
Am J Surg Pathol. 2012 Jun;36(6):851-6
22367296
World J Urol. 2015 Aug;33(8):1205-11
25373933
Am J Surg Pathol. 2011 Jul;35(7):962-70
21602658
Eur Urol. 2012 Apr;61(4):725-31
22172373
J Urol. 2004 Jun;171(6 Pt 1):2181-5, quiz 2435
15126781
Ann Surg Oncol. 2004 Jan;11(1):71-7
14699037
J Med Genet. 2008 Jun;45(6):321-31
18234728
Urology. 2005 Apr;65(4):681-6
15833508
Am J Surg Pathol. 2013 Oct;37(10):1490-504
24025520